Notícias da concorrência

Commission launches public consultation on antitrust rules for motor vehicle sector

Conteúdo da página

The European Commission has launched today a public consultation inviting all interested parties to express their views on the functioning of the competition rules applicable to vertical agreements in the automotive sector. These rules include the Motor Vehicle Block Exemption Regulation (‘MVBER’) and the Supplementary Guidelines (‘SGL’), both as amended in April 2023, as well as the Vertical Block Exemption Regulation (‘VBER’) and the Guidelines on vertical restraints, as far as they apply to the automotive sector.

The public consultation is part of the ongoing evaluation of the MVBER and the SGL launched on 18 January 2024. These rules, which assist companies in the automotive sector in assessing the compatibility of their vertical agreements with Article 101(1) of the Treaty on the functioning of the European Union (‘TFEU’), are currently set to expire on 31 May 2028.

In parallel, the Commission launched on 30 January 2025 the Strategic Dialogue on the Future of the Automotive Industry. The Commission will soon present an Action Plan which will address issues relevant for the automotive sector, such as ensuring access to talent and resources, technological innovation and the development of next-generation vehicles, and establishing a predictable regulatory framework. The MVBER evaluation complements these efforts by ensuring a competitive automotive aftermarket.

Background on the evaluation process

On 17 April 2023, the Commission  prolonged the MVBER for five years, until 31 May 2028, and updated the SGL to reflect the main technological developments in the automotive industry since 2010. This was the outcome of the previous evaluation of the framework, launched in 2018 and concluded on 28 May 2021, which indicated notably that the motor vehicle market was likely to evolve in the following years, due to the digitalisation of vehicles and new mobility patterns in particular.

The Commission launched the current evaluation on 18 January 2024 and a  call for evidence on 27 May 2024. In its review, the Commission will take into account the current competitive situation in the automotive sector and include an assessment of the impact of the 2023 amendments to the SGL. The evaluation will also consider how the market is likely to evolve until 2028 based on current trends.

Next steps

All interested parties can submit their comments by 23 May 2025. More information on how to submit a contribution is available here.

The Commission will analyse the responses to the consultation and publish a summary of the main points and conclusions on the Commission’s “Have your say” portal. On the same page, the Commission will also publish the contributions made to the public consultation in the language in which they were submitted.

As part of the ongoing evaluation, the Commission will also seek feedback from national competition authorities. In addition, the Commission is working with the Commission’s Joint Research Centre on a study to collect sector-specific information pertaining to a list of relevant industry indicators, with particular focus on the digital transformation of the automotive markets.

After the evaluation is finalised, the Commission will analyse the possible policy options for the future of the MVBER, in a policy-making phase planned for 2026. The progress of the evaluation can be followed on the Commission’s “Have your say” portal.

Background on the MVBER

Vertical agreements are agreements between two or more companies operating at different levels of the production or distribution chain, and relating to the conditions under which the parties may purchase, sell or resell certain goods or services.

Article 101(1) TFEU prohibits agreements between companies that restrict competition. However, under Article 101(3) TFEU, such agreements can be declared compatible with the Single Market, provided they contribute to improving the production or distribution of goods or to promoting technical or economic progress, while allowing consumers a fair share of the resulting benefits without eliminating competition.

The MVBER states that the Commission’s general regime (i.e., the VBER) applies to agreements for the distribution of new vehicles. The VBER exempts vertical agreements that meet certain conditions from the prohibition in Article 101(1) TFEU, thus creating a safe harbour for those agreements. The Guidelines on vertical restraints provide guidance on how to interpret and apply the VBER and how to assess vertical agreements falling outside the safe harbour of the VBER.

As to agreements relating to the sale or resale of spare parts for motor vehicles or the provision of repair and maintenance services for motor vehicles, the MVBER provides that Article 101(1) TFEU does not apply, so long as these agreements fulfil the requirements for an exemption under the general regime of the VBER and do not contain any of the severe restrictions of competition listed in the MVBER (such restrictions would remove the benefit of the exemption).

For More Information

More information on the upcoming steps of the current evaluation is available on the dedicated webpage of the Commission’s competition website.

Private healthcare market investigation

The Competition and Markets Authority (CMA) has completed its remittal into the private healthcare market and has brought article 22 of the 2014 Order into force.

From: Competition and Markets Authority Published7 March 2016Last updated28 February 2025 — See all updates

Case type: Markets Case state: Closed

Market sector: Healthcare and medical equipment Outcome: Markets – phase 2 adverse effect on competition leading to remedies Opened:4 April 2012Closed:28 April 2017

Contents

1. CMA letter to PHIN welcoming achievement of bronze compliance milestone
2. CMA publishes hospital action plans
   1. Plans published on 28 February 2025
   2. Plans published on 12 September 2024
   3. Plans published on 28 March 2024
3. Further CMA open letter to private healthcare consultants and hospitals
4. CMA open letter to private healthcare consultants and hospitals
5. CMA approval of PHIN’s Strategic Plan
6. Implementation of article 22 of the 2014 Order
   1. Timetable
   2. Final decision on material change of circumstances
   3. Hearing summary
   4. Responses to decision on material change of circumstances
   5. Provisional decision on material change of circumstances
   6. Responses to notice of intention
   7. Notice of intention
   8. Remedy group appointed
7. Remittal
   1. Timetable
   2. Contact
   3. Remittal final report
   4. Responses to remittal supplemental provisional decision on remedies
   5. Remittal provisional decision on remedies
   6. Hearing summaries
   7. Responses to the working papers
   8. Responses to remittal provisional decision on remedies
   9. Analysis
   10. Summaries of response hearings
   11. Responses to provisional findings and notice of possible remedies
   12. Provisional findings and notice of possible remedies
   13. Evidence
   14. Initial submissions
   15. Notifications
   16. Inquiry remittal group appointed
8. Phase 2
   1. Decisions on appeals
   2. Remedies
   3. Final order
   4. Draft orders
   5. Final report
   6. Core documents
   7. Undertakings
   8. Provisional findings report
   9. Annotated issues statement
   10. Analysis
   11. Working papers
   12. Surveys
   13. Evidence
   14. Responses to provisional decision on remedies
   15. Summaries of response hearings held with parties
   16. Responses to provisional findings report and notice of possible remedies
   17. Responses to working papers
   18. Responses to annotated issues statement
   19. Summaries of hearings held with parties
   20. Responses to issues statement
   21. Initial submissions – Third Parties
   22. Initial submissions – Main Parties
   23. Announcements
   24. News releases
9. Phase 1
   1. Action

La CNMC analiza la concentración Curium/Irab en segunda fase

Sector: Nota de prensa

Ámbito CNMC: Competencia

Compartir

• Curium notificó que adquiría el control exclusivo de Irab el 17 de octubre de 2024.
• La operación afecta al mercado de fabricación y comercialización de radiofármacos PET que se emplean en pruebas de detección de cáncer.
• La compra supone riesgos para la competencia, especialmente en el mercado de radiofármacos PET para diagnóstico del cáncer de próstata, y en la competencia potencial de estos mercados. 

La Comisión Nacional de los Mercados y la Competencia (CNMC) ha acordado, con fecha de 7 de febrero de 2025, el inicio de la segunda fase del análisis de la concentración Curium/Irab (C/1501/24).

La operación consiste en la adquisición del control exclusivo de Institut de Radiofarmacia Aplicada de Barcelona, S. L. (Irab) por parte de Curium Pharma Holding Spain, S. L. U. (Curium).

El sector económico afectado es el de la fabricación de productos farmacéuticos, en especial, la fabricación y comercialización de radiofármacos PET para diagnóstico del cáncer en los que solapan sus actividades.

La potencial adquisición puede suponer riesgos para la competencia, por lo que la CNMC analizará la operación en segunda fase. Este paso no prejuzga las conclusiones definitivas que puedan alcanzarse sobre la concentración.

Análisis previo

La CNMC ha analizado el funcionamiento y el nivel de competencia en los mercados afectados. En esta primera fase, ha encontrado elevadas cuotas conjuntas en varios de ellos, especialmente en el de radiofármacos PET para diagnóstico del cáncer de próstata. 

La operación también permitiría a Curium entrar en mercados y ámbitos geográficos en los que no estaba presente, lo que reforzaría su cartera de radiofármacos. 

Además, podría afectar al mercado de fabricación de radiofármacos PET en desarrollo para terceros, donde Irab juega un papel muy relevante. Ello podría afectar negativamente a la competencia potencial en estos mercados en España. 

Durante la segunda fase, se estudiarán estos posibles riesgos y su alcance. Irab y otros terceros con interés legítimo podrán presentar alegaciones. Curium también podrá formular alegaciones y aportar más información. Además, se solicitará un informe preceptivo a las comunidades autónomas en las que la concentración incida de forma significativa. 

La resolución final que apruebe la CNMC podrá autorizar, aceptar compromisos, imponer condiciones o prohibir la operación de concentración Curium/Irab. 

Documento no oficial, destinado a los medios de comunicación, y que no vincula a la CNMC. Reproducción permitida solo si se cita la fuente.

Decisões da concorrência

CDPQ / DIGITALBRIDGE / YONDR

Merger

M.11883

Last decision date: 28.02.2025 Simplified procedure

CMA

Lindab / HAS-Vent merger inquiry

• The Competition and Markets Authority (CMA) is investigating the completed acquisition by Lindab International AB of HAS-Vent Holdings Limited.
  • Updated: 28 February 2025

Autoridade da Concorrência de Portugal

ACO Cedar notifica a aquisição do controlo exclusivo sobre a Troiaresort e a Aqualuz Troia.

Ficha do processo

Ficha do processo

Temas relacionados

Acesse todos os clippings da concorrência

https://webadvocacy.com.br/category/clipping-da-concorrencia

Principiais sítios eletrônicos de defesa da concorrência do mundo

CADE – Conselho Administrativo de Defesa Econômica

FTC – Federal Trade Commission

USDOJ – Departamento de Justiça dos EUA

Comissão Europeia – Responsável pela política da concorrência na Europa

CMA – Autoridade da Concorrência do Reino Unido

Autorité de la Concurrence – Autoridade da Concorrência da França

AdC -Autoridade da Concorrência de Portugal

CNMC – Autoridade Concorrência da Espanha

CNDC – Autoridade Concorrência da Argentina

AGCM – Autoridade Concorrência da Itália

COFECE – Autoridade Concorrência do México